In Episode 1, Part 1, Jon Hamrick, Rena Goins and Bob Cochran discuss how 340B, the IRA, specialty therapies and launch planning have reshaped the role of commercial trade.

APIIC's Brian Doty says key starting materials are where domestic generic supply efforts must focus, and continuous flow chemistry makes the business case.

How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.

Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as ...

Bob Cochran, former senior director, trade relations at Incyte, discusses direct-to-patient models, specialty launches and ...

Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient ...

Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early. Market access teams can make individually ...

Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.

DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years ...

In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean ...